Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Hepatol. Apr 27, 2011; 3(4): 93-98
Published online Apr 27, 2011. doi: 10.4254/wjh.v3.i4.93
Table 1 Baseline characteristics of patients with primary biliary cirrhosis and controls
VariablesControls
PBC
P value
n = 151n = 180
Age (years)49.8 (20-72)56.3 (22-74)< 0.001
Female gender65 (43)165 (91.7)< 0.001
Caucasian123 (81.5)158 (87.8)0.1
AMA0 (0)137 (77.8)
BMI (kg/m2)28 (17-50)26.8 (17.6-51)0.09
Hypertension49 (32.5)48 (26.8)0.3
Diabetes21 (13.9)26 (14.5)0.9
Smoking96 (63.6)62 (35)< 0.001
Stage of diseasea0.001
0-228 (21.1)64 (38.6)
3-4105 (78.9)102 (61.4)
Total cholesterol (mg/dL)157.5 (73-320)216 (81-2055)< 0.001
LDL (mg/dL)80 (20-189)127 (12–539)< 0.001
HDL (mg/dL)48 (20-101)54 (17-163)0.001
Triglyceride (mg/dL)117 (19-2334)104 (32-736)0.2
Statin use2 (1.3)15 (8.3)0.004
CAD8 (5.3)14 (7.8)0.4
TIA2 (1.3)1 (0.6)0.6
Stroke0 (0)3 (1.7)0.3
Any CVD10 (6.6)18 (10)0.3
PBC: primary biliary cirrhosis; AMA: antimitochondrial antibody; BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; CAD: coronary artery disease; TIA: transient ischemic attack; CVD: cardiovascular disease. Continuous variables are expressed as median (range). Categorical variables are expressed as number (frequency).
aBased on the Metavir scoring system
Table 2 Serum lipid levels in different stages of primary biliary cirrhosis based on the Metavir scoring system
Stage 0-2Stage 3-4P value
Total cholesterol (mg/dL)229.5 (129-2055)210 (81-612)0.3
HDL (mg/dL)56 (20-102)53 (20-163)0.4
LDL (mg/dL)130.5 (52-239)127 (12-539)0.9
Triglyceride (mg/dL)128 (47-736)98.5 (32-462)0.008
PBC: primary biliary cirrhosis; HDL: high density lipoprotein; LDL: low density lipoprotein. Data are expressed as median (range).
Table 3 Characteristics of patients with asymptomatic and symptomatic primary biliary cirrhosis
VariablesAsymtomatic
Symptomatic
P value
n = 66n = 114
Age (years)56.7 (31-74)56.0 (22-73)0.4
Female gender58 (87.9)107 (93.9)0.2
Caucasian60 (90.9)98 (86)0.3
AMA50 (78.1)87 (77.7)1
BMI26.2 (19-43)27 (17.6-51)0.4
Hypertension19 (29.2)29 (25.4)0.6
Diabetes12 (18.5)14 (12.3)0.3
Smoking18 (28.6)44 (38.6)0.2
Stage of fibrosisa0.6
0-221 (35.6)43 (40.2)
3-438 (64.4)64 (59.8)
Total cholesterol (mg/dL)223.5 (84-2055)209.5 (81-612)0.06
LDL (mg/dL)134 (34-505)123 (12-539)0.2
HDL (mg/dL)57 (17-163)53 (20-118)0.5
Triglyceride (mg/dL)105 (32-527)104 (32-736)0.6
Statin use8 (12.1)7 (6.1)0.2
CAD3 (4.5)11 (9.6)0.22
TIA01 (0.9)1
Stroke0 (0)3 (2.6)0.3
Any CVD3 (4.5)15 (13.2)0.06
PBC: primary biliary cirrhosis; AMA: antimitochondrial antibody; BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; CAD: coronary artery disease; TIA: transient ischemic attack; CVD: cardiovascular disease. Continuous variables are expressed as median (range). Categorical variables are expressed as number (frequency).
aBased on the Metavir scoring system
Table 4 Characteristics of cases with and without fatigue
With fatigue
Without fatigue
P value
n = 74n = 104
Age (years)54.3 (22-73)57.1 (31-74)0.4
Female gender71 (95.9)92 (88.5)0.08
Caucasian63 (85.1)93 (89.4)0.4
AMA57 (77)79 (78.2)0.9
BMI (kg/m2)27 (17.6-39.2)26.2 (17.6-51)0.4
Hypertension18 (24.3)29 (28.2)0.6
Diabetes10 (13.5)15 (14.6)0.8
Smoking26 (35.1)36 (35.6)0.9
Stage of fibrosisa0.7
0-226 (37.1)38 (40.4)
3-444 (62.9)56 (59.6)
Total cholesterol (mg/dL)203 (83-612)217 (81-2055)0.06
LDL (mg/dL)123.5 (29-539)131 (12-505)0.2
HDL (mg/dL)55 (20-118)54 (17-163)0.5
Triglyceride (mg/dL)110 (32-462)104 (32-736)0.6
Statin use6 (8.1)9 (8.7)0.9
CAD7 (9.5)7 (6.7)0.5
TIA1 (1.4)0 (0)0.4
Stroke2 (2.7)0 (0)0.2
Any CVD10 (13.5)7 (6.7)0.1
AMA: antimitochondrial antibody; BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; CAD: coronary artery disease; TIA: transient ischemic attack; CVD: cardiovascular disease. Continuous variables are expressed as median (range). Categorical variables are expressed as number (frequency).
aBased on the Metavir scoring system